Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bouchaud

Showing results (591-600 of 631) with videos related to

Pageof 64
Sort By:
Journal of Fungi (Basel, Switzerland)|May 28, 2022
Invasive Rhinosinusitis Caused by <i>Alternaria infectoria</i> in a Patient with Autosomal Recessive CARD9 Deficiency and a Review of the LiteratureOlivier Paccoud, Nicolas Vignier, Mohammed Boui, et al.
Pharmacotherapy|March 1, 2019
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL StudyMinh Patrick Lê, Marc-Antoine Valantin, Lambert Assoumou, et al.
The Journal of Antimicrobial Chemotherapy|September 21, 2020
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' responseChristine Katlama, Lambert Assoumou, Marc-Antoine Valantin, et al.
Frontiers in Nutrition|December 8, 2025
Efficacy of fermented foods for the prevention and treatment of bacterial vaginosis and vulvovaginal candidiasisAslı Akpınar, Lidia Hanna Markiewicz, Hayriye Şebnem Harsa, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2019
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL studyChristine Katlama, Lambert Assoumou, Marc-Antoine Valantin, et al.
Diabetes & Metabolism|March 5, 2024
BedBiopsy: Diagnostic performance of bedside ultrasound-guided bone biopsies for the management of diabetic foot infectionNolan Hassold, Hélène Bihan, Yolène Pambo Moumba, et al.
Revue Des Maladies Respiratoires|February 20, 2022
[RESPIRenT: Pneumology network of innovation and translational research, a second wind for J2R]I Annesi-Maesano, P Bonniaud, G Bouchaud, et al.
Allergy|June 13, 2019
Overview of in vivo and ex vivo endpoints in murine food allergy models: Suitable for evaluation of the sensitizing capacity of novel proteins?Laure Castan, Katrine L Bøgh, Natalia Z Maryniak, et al.
Cancer Research|May 17, 2008
The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancerCécile Badoual, Grégory Bouchaud, Nour El Houda Agueznay, et al.
Journal of Virology|February 11, 2021
A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II TrialY Lévy, C Lacabaratz, E Lhomme, et al.
Pageof 64

Showing results (591-600 of 631) with videos related to

Sort By:
Pageof 64
Journal of Fungi (Basel, Switzerland)|May 28, 2022
Invasive Rhinosinusitis Caused by <i>Alternaria infectoria</i> in a Patient with Autosomal Recessive CARD9 Deficiency and a Review of the LiteratureOlivier Paccoud, Nicolas Vignier, Mohammed Boui, et al.
Pharmacotherapy|March 1, 2019
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL StudyMinh Patrick Lê, Marc-Antoine Valantin, Lambert Assoumou, et al.
The Journal of Antimicrobial Chemotherapy|September 21, 2020
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' responseChristine Katlama, Lambert Assoumou, Marc-Antoine Valantin, et al.
Frontiers in Nutrition|December 8, 2025
Efficacy of fermented foods for the prevention and treatment of bacterial vaginosis and vulvovaginal candidiasisAslı Akpınar, Lidia Hanna Markiewicz, Hayriye Şebnem Harsa, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2019
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL studyChristine Katlama, Lambert Assoumou, Marc-Antoine Valantin, et al.
Diabetes & Metabolism|March 5, 2024
BedBiopsy: Diagnostic performance of bedside ultrasound-guided bone biopsies for the management of diabetic foot infectionNolan Hassold, Hélène Bihan, Yolène Pambo Moumba, et al.
Revue Des Maladies Respiratoires|February 20, 2022
[RESPIRenT: Pneumology network of innovation and translational research, a second wind for J2R]I Annesi-Maesano, P Bonniaud, G Bouchaud, et al.
Allergy|June 13, 2019
Overview of in vivo and ex vivo endpoints in murine food allergy models: Suitable for evaluation of the sensitizing capacity of novel proteins?Laure Castan, Katrine L Bøgh, Natalia Z Maryniak, et al.
Cancer Research|May 17, 2008
The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancerCécile Badoual, Grégory Bouchaud, Nour El Houda Agueznay, et al.
Journal of Virology|February 11, 2021
A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II TrialY Lévy, C Lacabaratz, E Lhomme, et al.
Pageof 64